Analysts forecast that Icon Plc (NASDAQ:ICLR) will announce $455.45 million in sales for the current quarter, Zacks reports. Eight analysts have issued estimates for Icon’s earnings, with estimates ranging from $450.00 million to $461.74 million. Icon posted sales of $435.13 million in the same quarter last year, which suggests a positive year over year growth rate of 4.7%. The business is expected to announce its next earnings report before the market opens on Thursday, February 15th.
On average, analysts expect that Icon will report full year sales of $455.45 million for the current financial year, with estimates ranging from $1.75 billion to $1.76 billion. For the next year, analysts forecast that the firm will report sales of $1.90 billion per share, with estimates ranging from $1.88 billion to $1.91 billion. Zacks’ sales averages are a mean average based on a survey of research firms that cover Icon.
Icon (NASDAQ:ICLR) last released its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.03. Icon had a net margin of 16.37% and a return on equity of 28.42%. The firm had revenue of $440.30 million during the quarter, compared to analysts’ expectations of $438.09 million. During the same period in the previous year, the business posted $1.19 earnings per share. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year.
Several institutional investors have recently added to or reduced their stakes in the company. IHT Wealth Management LLC increased its stake in shares of Icon by 16.9% in the second quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock valued at $223,000 after buying an additional 24 shares during the period. Bangor Savings Bank increased its stake in shares of Icon by 1.4% in the second quarter. Bangor Savings Bank now owns 11,539 shares of the medical research company’s stock valued at $1,128,000 after buying an additional 161 shares during the period. D.A. Davidson & CO. increased its stake in shares of Icon by 7.8% in the second quarter. D.A. Davidson & CO. now owns 4,761 shares of the medical research company’s stock valued at $465,000 after buying an additional 345 shares during the period. MML Investors Services LLC increased its stake in shares of Icon by 9.0% in the second quarter. MML Investors Services LLC now owns 4,983 shares of the medical research company’s stock valued at $487,000 after buying an additional 413 shares during the period. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Icon by 11.0% in the second quarter. Cubist Systematic Strategies LLC now owns 4,844 shares of the medical research company’s stock valued at $474,000 after buying an additional 481 shares during the period. 89.65% of the stock is owned by institutional investors.
Shares of Icon (NASDAQ:ICLR) traded up $2.02 during trading on Monday, hitting $113.97. 488,900 shares of the stock were exchanged, compared to its average volume of 300,323. The company has a market capitalization of $6,120.00, a PE ratio of 22.13, a PEG ratio of 1.62 and a beta of 0.61. Icon has a 52 week low of $76.46 and a 52 week high of $124.48. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/22/455-45-million-in-sales-expected-for-icon-plc-iclr-this-quarter.html.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.